DeGolyer Donald W sold $126K of EBS
DeGolyer Donald W sold 17,800 shares of Emergent BioSolutions Inc. (EBS) at $7.09 ($0.13M total) on 2026-10-07 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest in size and may generate slight short‑term pressure on the stock, but is unlikely to move the market significantly.
Market read
Primary insider sale filing; modest relevance for traders monitoring EBS.
What to watch
The director's sale was pre‑arranged under a 10b5‑1 plan, reducing the informational content of the trade.
Background
SEC Form 4 filing discloses an insider transaction by a director of Emergent BioSolutions.
Ticker impact
Director DeGolyer sold 17,800 shares for $126,202 via a 10b5-1 plan, reducing his stake to 111,921 shares.
likely slight downward pressure as the market prices the insider sale
Form 4 filings are primary source; a director selling $126k is a tangible sell signal, though the amount is modest.
Market effects
Minimal impact on the broader biotech sector; insider sales are routine.
No regional effect beyond the company's stock.
Limited to investors tracking EBS.
Counterpoint
The sale could be a routine liquidity event and not indicative of negative fundamentals.
Key entities
- companyEmergent BioSolutions Inc.
Biopharmaceutical company whose director sold shares.
- personDeGolyer Donald W
Director of Emergent BioSolutions executing a 10b5‑1 sale.
